Table 2.
Demographics and medications
| Variable | Standard diet (n = 39) |
Modified diet (n = 35) |
||||
|---|---|---|---|---|---|---|
| n (%) | Median | (Min, max) | n (%) | Median | (Min, max) | |
| Male sex | 26 (66.7%) | 25 (71.4%) | ||||
| White ethnicity | 38 (97.4%) | 33 (94.3%) | ||||
| Diabetes as a comorbidity | 10 (25.6%) | 17 (48.6%) | ||||
| Diabetes as a cause of ESKD | 8 (20.5%) | 14 (40%) | ||||
| Age, yr | 59.9 | (28.7, 88.3) | 61.0 | (29.3, 84.9) | ||
| Baseline dry weight, kg | 81.5 | (57.5, 149.1) | 80.0 | (49, 132) | ||
| End of intervention dry weight, kg | 80.9 | (58, 150) | 79.8 | (49, 134) | ||
| Height, m | 1.70 | (1.51, 1.86) | 1.67 | (1.47, 1.87) | ||
| BMI, kg/m2 | 28.4 | (21.8, 48.9) | 27.7 | (17.9, 48.4) | ||
| IBW, kg | 71.2 | (57.3, 86.2) | 67.7 | (49, 83.7) | ||
| Recommended protein intake 1.1 g/kg IBW | 78.3 | (63, 94.8) | 74.5 | (53.9, 92.1) | ||
| Baseline serum phosphate, mg/dl | 5.92 | (3.53, 12.1) | 6.13 | (3.90, 10.2) | ||
| Baseline urea reduction ratio, % | 71.8 | (40.4, 84) | 70 | (58, 83) | ||
| Baseline bicarbonate, mEq/l | 22 | (18, 26) | 23.5 | (17.6, 29.6) | ||
| Medicationsa,b | ||||||
| Vitamin D native IU | 11 (28%) | 800 | (343, 7142.9) | 10 (29%) | 800 | (200, 5714) |
| Alfacalcidol, μg | 23 (59%) | 0.5 | (0.11, 1.0) | 20 (57%) | 0.37 | (0.25, 1.0) |
| Paricalcitol oral, μg | 4 (10%) | 2 | (1.43, 4) | 7 (20%) | 1.71 | (1, 2) |
| Paricalcitol i.v., μg | 3 (8%) | 1.07 | (0.86, 2.14) | 1 (3%) | 2.14 | NA |
| Calcitriol, μg | 0 (0%) | NA | NA | 1 (3%) | 12.5 | NA |
| Cinacalcet, mg | 5 (13%) | 60 | (30, 120) | 6 (17%) | 60 | (30, 120) |
| Bindersa,b | ||||||
| Sevelamer carbonate, mg | 14 (36%) | 7200 | (800, 9600) | 12 (35%) | 4800 | (1600, 14400) |
| Sevelamer hydrochloride, mg | 9 (23%) | 4800 | (1600, 7200) | 8 (24%) | 4800 | (2400, 7200) |
| Calcium carbonate, mg | 4 (10%) | 1500 | (1250, 3000) | 1 (3%) | 1500 | (1500, 1500) |
| Calcium acetate, mg | 12 (31%) | 2500 | (1000, 4000) | 13 (38%) | 3000 | (1000, 3000) |
| Calcium acetate magnesium carbonate, mg | 1 (3%) | 870 | NA | 0 (0%) | NA | |
| Lanthanum carbonate, mg | 4 (10%) | 2625 | (1500, 4000) | 2 (6%) | 3500 | (3000, 4000) |
| Sucroferric oxyhydroxide, mg | 3 (8%) | 1500 | (3, 1500) | 5 (15%) | 1500 | (1500, 1500) |
| Alucaps, mg | 1 (3%) | 1425 | NA | 0 (0%) | NA | |
BMI, body mass index; ESKD, end-stage kidney disease; IBW, ideal body weight; NA, not applicable.
a
Number of patients on the medication/binder by trial arm.
b
Median intake of patients on the medication/binder by trial arm, with associated minimum and maximum amounts.